Filtered By:
Source: The American Journal of Emergency Medicine
Drug: Warfarin

This page shows you your search results in order of date.

Order by Relevance | Date

Total 6 results found since Jan 2013.

Throwing it in reverse: An update on reversal of oral factor Xa inhibitors
In recent years, the use of oral Factor Xa (FXa) inhibitors such as rivaroxaban and apixaban, have seen more extensive utilization for stroke prevention in non-valvular atrial fibrillation and the prevention/treatment of venous thromboembolisms [1,2]. Some studies have shown a similar bleed risk between FXa inhibitors and warfarin while other studies demonstrated a decreased risk for a bleed with FXa inhibitors. Despite a possible decreased risk, the paucity of data available for treating an acute major bleed due to FXa inhibitors has led some clinicians to shy away from their use.
Source: The American Journal of Emergency Medicine - April 7, 2019 Category: Emergency Medicine Authors: Brian W. Gilbert, Jacob A. Reeder, Mohammed A. Alkhalifah, David A. Moran, Michael A. Corvino Source Type: research

Management of Factor Xa inhibitor-associated life-threatening major hemorrhage: A retrospective multi-center analysis
This study describes a cohort of patients with FXa inhibitor-associated life-threatening bleeding events, their clinical characteristics, interventions and outcomes.
Source: The American Journal of Emergency Medicine - August 19, 2017 Category: Emergency Medicine Authors: Truman J. Milling, Carol L. Clark, Charles Feronti, Shlee S. Song, Sam S. Torbati, Gregory J. Fermann, Jeffrey Weiss, Dony Patel Source Type: research

Stroke prevention in real-life practice
We have greatly enjoyed reading the recently published article by McIntyre et al [1] . The authors distributed a 16-question, Web-based survey to Canadian residency programs and each scenario involved a 76-year-old man with new atrial fibrillation (AF) and a CHADS2 score of 3. The authors revealed the discordance between clinical guidelines for stroke prevention in AF and the practice of Canadian emergency medicine residents. Despite ranking the risk of adverse events as their most important consideration and the superior safety profile of those non –vitamin K antagonist oral anticoagulants (NOACs), residents underused ...
Source: The American Journal of Emergency Medicine - June 5, 2016 Category: Emergency Medicine Authors: Özcan Başaran, Volkan Doğan, Eda Özlek, Bülent Özlek, Murat Biteker Tags: Correspondence Source Type: research

Stroke Prevention in Real-life Practice
We have greatly enjoyed reading the recently published article by McIntyre et al. (1). The authors distributed a 16-question, web-based survey to Canadian residency programs and each scenario involved a 76-year-old man with new atrial fibrillation (AF) and a CHADS2 score of 3. The authors revealed the discordance between clinical guidelines for stroke prevention in AF and the practice of Canadian emergency medicine residents. Despite ranking the risk of adverse events as their most important consideration and the superior safety profile of that non-vitamin K antagonist oral anticoagulants (NOACs), residents underused this ...
Source: The American Journal of Emergency Medicine - June 5, 2016 Category: Emergency Medicine Authors: Özcan Başaran, Volkan Doğan, Eda Özlek, Bülent Özlek, Murat Biteker Source Type: research

Painless aortic dissection: thrombolytic and antithrombotic vigilance
We thank Huang et al for their interesting article on identification of painless aortic dissection (AD) before thrombolytic treatment for acute ischemic stroke. We would like to emphasize the importance of being vigilant to AD before initiating any contraindicated therapy. We recently had an 84-year-old man with history of atrial fibrillation and transient ischemic attack who presented to the emergency department with acute shortness of breath without chest pain. The symptom contributed to atrial fibrillation with rapid ventricular response. Chest x-ray showed increased soft tissue prominence of the aortic arch suspicious ...
Source: The American Journal of Emergency Medicine - May 20, 2013 Category: Emergency Medicine Authors: Promporn Suksaranjit, Kunatum Prasidthrathsint, Wonngarm Kittanamongkolchai, Supawat Ratanapo, Narat Srivali, Daych Chongnarungsin Tags: Correspondence Source Type: research

Subconjunctival hemorrhage in a patient on dabigatran (Pradaxa)
Dabigatran is a direct thrombin inhibitor that has gained increasing popularity for prevention of thromboembolic events such as stroke, pulmonary embolism, and myocardial ischemia. Because of the increasing use of this drug, emergency department (ED) physicians are going to be evaluating patients taking this medication. It is important to understand the potential for ocular bleeding complications associated with this class of anticoagulant. Traditionally, patients have been placed on vitamin K antagonists to decrease the risk of thromboembolism. In the RE-LY and RE-COVER studies, dabigatran showed non-inferiority to coumad...
Source: The American Journal of Emergency Medicine - September 24, 2012 Category: Emergency Medicine Authors: Tam M. Nguyen, Michael P. Phelan, Xiang Q. Werdich, Paul J. Rychwalski, Christopher M. Huff Tags: Case Reports Source Type: research